Valuation: NovoCure Limited

Capitalization 1.2B 1.03B 949M 894M 1.66B 112B 1.7B 11.14B 4.36B 53.77B 4.52B 4.42B 192B P/E ratio 2026 *
-6.89x
P/E ratio 2027 * -9.08x
Enterprise value 989M 842M 780M 734M 1.37B 91.98B 1.4B 9.15B 3.58B 44.17B 3.71B 3.63B 157B EV / Sales 2026 *
1.42x
EV / Sales 2027 * 1.59x
Free-Float
90.74%
Yield 2026 *
-
Yield 2027 * -
1 day-3.82%
1 week+0.28%
Current month-2.94%
1 month-11.91%
3 months-25.39%
6 months-21.57%
Current year-18.17%
1 week 10.14
Extreme 10.135
11.32
1 month 10.14
Extreme 10.135
12.84
Current year 9.82
Extreme 9.82
15.46
1 year 9.82
Extreme 9.82
20.06
3 years 9.82
Extreme 9.82
83.6
5 years 9.82
Extreme 9.82
232.76
10 years 5.95
Extreme 5.95
232.76
Manager TitleAgeSince
Chief Executive Officer 46 30/11/2025
Director of Finance/CFO 52 31/12/2024
Chief Tech/Sci/R&D Officer - 16/01/2023
Director TitleAgeSince
Director/Board Member 58 31/12/2011
Chairman 63 31/12/2008
Director/Board Member 65 04/08/2011
Change 5d. change 1-year change 3-years change Capi.($)
-3.82%+0.28%-35.88%-83.51% 1.2B
+0.08%-0.18%+21.10%+18.93% 12.97B
-0.01%-0.15%+15.87%-6.72% 9.31B
+0.34%+0.91%+63.10%+48.70% 5.89B
+0.26%+0.39%+1.21%-25.43% 5.65B
+0.96%+1.80%-12.47%+52.75% 5.36B
+1.21%-1.87%-5.81%+2.68% 4.77B
+0.87%-0.64% - - 3.91B
+2.14%+3.41%+14.13%-45.93% 1.83B
+3.79%+7.29%+83.61%+134.76% 1.51B
Average +0.58%+1.10%+16.10%+10.69% 5.24B
Weighted average by Cap. +0.45%+0.34%+16.79%+13.21%

Financials

2026 *2027 *
Net sales 695M 592M 548M 516M 961M 64.61B 980M 6.43B 2.51B 31.03B 2.61B 2.55B 111B 758M 646M 598M 563M 1.05B 70.49B 1.07B 7.01B 2.74B 33.85B 2.84B 2.78B 121B
Net income -178M -152M -140M -132M -246M -16.55B -251M -1.65B -644M -7.95B -668M -654M -28.32B -133M -113M -105M -98.45M -183M -12.33B -187M -1.23B -480M -5.92B -498M -487M -21.1B
Net Debt -215M -183M -170M -160M -297M -20B -303M -1.99B -778M -9.6B -807M -790M -34.21B -
Logo NovoCure Limited
NovoCure Limited is a global oncology company. The Company is engaged in the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua for the treatment of solid tumor cancers. Its commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. It is conducting pivotal studies evaluating the use of TTFields in the treatment of ovarian cancer, brain metastases from non-small cell lung cancer (NSCLC) (brain metastases) and pancreatic cancer. Its key priorities are to drive commercial adoption of Optune, its commercial TTFields device. It also has a license to market Optune in China, Hong Kong, Macau and Taiwan. It has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.
Employees
1,605
Date Price Change Volume
10/04/26 10.58 $ -3.82% 809,736
09/04/26 11.00 $ +1.95% 977,581
08/04/26 10.79 $ +4.25% 1,194,774
07/04/26 10.35 $ -1.90% 941,916
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
10.58USD
Average target price
25.07USD
Spread / Average Target
+136.97%

Quarterly revenue - Rate of surprise